<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03038230</url>
  </required_header>
  <id_info>
    <org_study_id>MCLA-117-CL01</org_study_id>
    <secondary_id>2015-003704-23</secondary_id>
    <nct_id>NCT03038230</nct_id>
  </id_info>
  <brief_title>MCLA-117 in Acute Myelogenous Leukemia</brief_title>
  <official_title>A Phase 1, Multinational Study of MCLA-117 in Acute Myelogenous Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merus N.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merus N.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a First-in-Human, single arm, open-label, multi-national study designed to determine&#xD;
      the safety, tolerability and preliminary efficacy of MCLA 117.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design :&#xD;
&#xD;
      This open label, single arm, multinational, first-in-human study consists of 2 parts. Part 1&#xD;
      consists of dose escalation cohorts and Part 2 is a dose expansion cohort.&#xD;
&#xD;
      The study population will include adult AML patients (and all subtypes of AML, except for&#xD;
      APL) with relapse or refractory disease and newly diagnosed elderly untreated AML patients&#xD;
      with high risk cytogenetics. In addition, very high-risk MDS patients with relapsed or&#xD;
      refractory disease are eligible.&#xD;
&#xD;
      In Part 1, dose escalations cohorts are followed until dose-limiting toxicity (DLT) or a&#xD;
      maximum tolerated dose (MTD) or RecommendedPart2Dose (RP2D) is defined. Dose escalation&#xD;
      decisions will be made by the Data Review Committee and will be primarily guided by safety&#xD;
      data observed through the end of Cycle 1, as well as on-going assessment of safety beyond&#xD;
      Cycle 1 in later cohorts.&#xD;
&#xD;
      Part 2 will begin once the MTD or RP2D is determined in Part 1. Part 2 will further&#xD;
      characterize the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD),&#xD;
      immunogenicity and to assess preliminary efficacy of MCLA-117. This part will enroll&#xD;
      approximately 30 evaluable patients (defined as evaluable for first efficacy assessment).&#xD;
&#xD;
      For both parts, the study consists of 3 periods: a Screening period (up to 28 days prior to&#xD;
      the first dose of study drug); a Treatment period (first dose of study drug until the last&#xD;
      dose of study drug with treatment cycles of 28 days); and a Follow Up period (through 30 days&#xD;
      after the last dose and quarterly checks for survival data for up to 1 year). Participants'&#xD;
      safety will be monitored throughout the study. Patients will be permitted to receive MCLA-117&#xD;
      beyond Cycle 1 if conditions allow this.&#xD;
&#xD;
      Number of Sites:&#xD;
&#xD;
      Approximately 15 centers in five countries are estimated to be involved during Parts 1 and 2&#xD;
      of the study. Additional sites may be added to ensure there is an acceptable enrollment rate&#xD;
      or to replace non-enrolling/withdrawn sites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Dose Limiting Toxicities (DLT)</measure>
    <time_frame>28 days</time_frame>
    <description>Evaluation of number of participants with treatment related toxicity observed during a dose escalation step for 1 Cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration [Cmax]</measure>
    <time_frame>Day 22 predose, 5 minutes prior to End of Infusion (EOI), 1h, 2h, 4h, 8h, 24h, 72h, 6 days after EOI</time_frame>
    <description>Maximum plasma concentration [Cmax] as measured from all individual plasma concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of plasma</measure>
    <time_frame>Day 22 predose, 5 minutes prior to End of Infusion (EOI), 1h, 2h, 4h, 8h, 24h, 72h, 6 days after EOI</time_frame>
    <description>Clearance of plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state [Vss]</measure>
    <time_frame>Day 22 predose, 5 minutes prior to End of Infusion (EOI), 1h, 2h, 4h, 8h, 24h, 72h, 6 days after EOI</time_frame>
    <description>Volume of distribution at steady state [Vss]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration [Tmax]</measure>
    <time_frame>Day 22 predose, 5 minutes prior to End of Infusion (EOI), 1h, 2h, 4h, 8h, 24h, 72h, 6 days after EOI</time_frame>
    <description>Time to reach maximum plasma concentration [Tmax]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life [t1/2]</measure>
    <time_frame>Day 22 predose, 5 minutes prior to End of Infusion (EOI), 1h, 2h, 4h, 8h, 24h, 72h, 6 days after EOI</time_frame>
    <description>Half-life [t1/2] calculated as time from all individual plasma concentrations to reach 50% of maximum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve from time zero to time t [AUC0-t]</measure>
    <time_frame>1 week</time_frame>
    <description>Area under the concentration versus time curve [AUC0-t]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AntiDrugAntibodies (ADA) against MCLA-117</measure>
    <time_frame>24 months</time_frame>
    <description>Number of participants with ADAs against MCLA-117 as measured in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum titer of ADAs against MCLA-117</measure>
    <time_frame>Day 1 of each cycle</time_frame>
    <description>Serum titer of ADAs against MCLA-117 as measured in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum titer of ADAs against MCLA-117</measure>
    <time_frame>Day 28 of each cycle</time_frame>
    <description>Serum titer of ADAs against MCLA-117 as measured in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine levels</measure>
    <time_frame>Cycle 1: Day 1, 4, 8 and 28 at predose, 4h and 24h after end of infusion</time_frame>
    <description>Change in profile of cytokine upon administration of MCLA-117 compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of myeloblasts</measure>
    <time_frame>Day 1 of every cycle and through study completion, an average of 2 months</time_frame>
    <description>number of blasts in peripheral blood and in bone marrow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response</measure>
    <time_frame>Day 1 of every cycle and through study completion, an average of 2 months</time_frame>
    <description>Objective response is assessed by Cheson 2003</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>MCLA-117 bispecific antibody</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation cohorts, with escalating doses of MCLA-117 until MTD or RP2D is reached. The dose is given weekly after initial ramp-up dosing steps. Each Cycle is 28 days. Single agent treatment.&#xD;
Part 2-Expansion Cohort: The RP2D of MCLA-117 is given weekly after initial ramp-up dosing steps. Each Cycle is 28 days. Single agent treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCLA-117 bispecific antibody</intervention_name>
    <description>MCLA-117, a human bispecific IgG antibody which targets CLEC12A and CD3</description>
    <arm_group_label>MCLA-117 bispecific antibody</arm_group_label>
    <other_name>bispecific</other_name>
    <other_name>human bispecific common light chain</other_name>
    <other_name>bispecific IgG1 targeting CLEC12A and CD3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female age ≥18 years old;&#xD;
&#xD;
          2. Signed informed consent form&#xD;
&#xD;
          3. One of the two following:&#xD;
&#xD;
             i) AML either de novo or secondary [any subtype except acute promyelocytic leukemia&#xD;
             (APL)] who either:&#xD;
&#xD;
               1. are in relapse to standard therapy following an initial response&#xD;
&#xD;
               2. failed primary induction therapy with no CR (failed ≥2 courses of intensive&#xD;
                  induction therapy. Intensive chemotherapy defined as an intensity of ≥ 5+2)&#xD;
&#xD;
               3. newly diagnosed untreated AML in patients ≥ 65 years of age with high risk&#xD;
                  cytogenetics, if they are not candidates for standard available induction&#xD;
                  chemotherapy&#xD;
&#xD;
               4. AML secondary to MDS, either relapsed or refractory, previously treated with&#xD;
                  hypomethylating agents for at least 4 cycles;&#xD;
&#xD;
               5. Relapsed or refractory AML unfit for intensive chemotherapy previously treated&#xD;
                  with a low intensity regimen (e.g. low dose Ara-c, hypomethylating agent, etc.)&#xD;
                  including Venetoclax for at least 2 cycles;&#xD;
&#xD;
             OR ii) MDS patients who meet the following criteria: very high-risk disease (IPSS-R&#xD;
             score &gt; 6, Greenberg et al., 2012), either relapsed or refractory, previously treated&#xD;
             with hypomethylating agents for at least 4 cycles;&#xD;
&#xD;
          4. Must have baseline BM sample taken by BMA/BMB within 28 days prior to first dose of&#xD;
             MCLA-117 for CLEC12A detection;&#xD;
&#xD;
          5. Estimated life expectancy of at least 8 weeks;&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;&#xD;
&#xD;
          7. Significant toxicities incurred as a result of previous anti-cancer therapy resolved&#xD;
             to ≤ Grade 1 (NCI-CTCAE version 4.03);&#xD;
&#xD;
          8. Acceptable laboratory values at screening;&#xD;
&#xD;
          9. Male patients must agree to use an adequate and medically accepted method of&#xD;
             contraception throughout the study and for at least 6 months after if their sexual&#xD;
             partners are women of child bearing potential (WOCBP).&#xD;
&#xD;
         10. WOCBP must be using highly effective and medically accepted method of contraception to&#xD;
             avoid pregnancy throughout the study and for at least 6 months after the study ;&#xD;
&#xD;
         11. WOCBP must have a negative serum or urine pregnancy test within 72 hours prior to the&#xD;
             start of study drug.&#xD;
&#xD;
         12. Peripheral blast count &lt;/= 30,000/mm3 at the time of initiation of infusion on Cycle 1&#xD;
             Day 1.&#xD;
&#xD;
         13. Able and willing to comply with all study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of chronic myelogenous leukemia in blast crisis;&#xD;
&#xD;
          2. Prior hematopoietic stem cell transplantation (this exclusion applies for dose&#xD;
             escalation Part 1 and Cohort A of Part 2);&#xD;
&#xD;
          3. For patients in Cohort B of Part 2, prior hematopoietic stem cell transplantation is&#xD;
             allowed under certain circumstances.&#xD;
&#xD;
          4. Treatment with anticancer medications, investigational drugs or radiotherapy is&#xD;
             allowed within 2 weeks or 5 half-lives prior to start of MCLA-117;&#xD;
&#xD;
          5. Previous receipt of live vaccines in the 4 weeks prior to study drug administration;&#xD;
&#xD;
          6. Chronic concurrent need of use of corticosteroids &gt; 10 mg/day of oral prednisone or&#xD;
             the equivalent, except topical preparations (e.g., topical creams, steroid inhaler,&#xD;
             nasal spray or ophthalmic solution);&#xD;
&#xD;
          7. Use of immunosuppressant medications within 4 weeks of MCLA-117 administration;&#xD;
&#xD;
          8. Clinically active central nervous system (CNS) leukemia;&#xD;
&#xD;
          9. Patients who are pregnant or lactating;&#xD;
&#xD;
         10. Patients with an active infection or with an unexplained fever during screening or on&#xD;
             the first scheduled day of dosing;&#xD;
&#xD;
         11. Patients with known hypersensitivity to any of the components of MCLA-117 or who have&#xD;
             had prior hypersensitivity reactions to human or humanized monoclonal antibodies;&#xD;
&#xD;
         12. Patients with known HIV, hepatitis B or C;&#xD;
&#xD;
         13. Patients with New York Heart Association Class III or IV congestive heart failure or&#xD;
             left ventricular ejection fraction (LVEF) &lt; 50%, or significant uncontrolled cardiac&#xD;
             disease, current diagnosis of unstable angina, uncontrolled congestive heart failure,&#xD;
             new myocardial infarction, or ventricular arrhythmia requiring medication;&#xD;
&#xD;
         14. Prior malignancy (other than basal cell carcinoma and cervical in situ carcinoma)&#xD;
             unless treated with a curative intend and without evidence of malignant disease for 1&#xD;
             year before screening. Patients with prior hematologic malignancies that have&#xD;
             progressed to AML (such as Myelodysplastic syndrome, myeloproliferative neoplasms,&#xD;
             bi-phenotypic leukemias, AcuteLymphocyticLeukemia) or AML that has relapsed are&#xD;
             eligible;&#xD;
&#xD;
         15. Urinary protein &gt;2+ possibly indicative of renal disease. If the 24 hours urine&#xD;
             protein shows a result of &lt; 100 mg protein, subject can be eligible;&#xD;
&#xD;
         16. Patients with any other medical or psychological condition deemed by the Investigator&#xD;
             to be likely to interfere with a patient's ability to sign informed consent, cooperate&#xD;
             and participate in the study, or interfere with the interpretation of the results;&#xD;
&#xD;
         17. WOCBP or males with a WOCB partners not willing to use highly effective and medically&#xD;
             accepted methods of contraception for 6 months after last study drug administration.&#xD;
&#xD;
         18. Need for concurrent other cytoreductive chemotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Cortes, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Independent Protocol Advisor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgia Cancer Center, Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas, MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Netwerk Antwerpen Campus Stuivenberg</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <state>Ile-de-France</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Tor Vergata</name>
      <address>
        <city>Rome</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC, location VUmc</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1081HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 26, 2017</study_first_submitted>
  <study_first_submitted_qc>January 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2017</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>human bispecific full length IgG antibody, CLEC12A, CD3</keyword>
  <keyword>MCLA-117</keyword>
  <keyword>First in Human</keyword>
  <keyword>Antibodies, Bispecific</keyword>
  <keyword>Immunologic Factors</keyword>
  <keyword>relapsed, refractory patient</keyword>
  <keyword>AML, minimal residual disease (MRD)</keyword>
  <keyword>Acute Myelogenous Leukemia</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>CD34+CD38</keyword>
  <keyword>T-cell recruiting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Bispecific</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03038230
org study id: MCLA-117-CL01
secondary id: 2015-003704-23
nct id: NCT03038230
lead sponsor: 
has dmc: Yes
This is a First-in-Human, single arm, open-label, multi-national study designed to determine
      the safety, tolerability and preliminary efficacy of MCLA 117.
Study Design :

      This open label, single arm, multinational, first-in-human study consists of 2 parts. Part 1
      consists of dose escalation cohorts and Part 2 is a dose expansion cohort.

      The study population will include adult AML patients (and all subtypes of AML, except for
      APL) with relapse or refractory disease and newly diagnosed elderly untreated AML patients
      with high risk cytogenetics. In addition, very high-risk MDS patients with relapsed or
      refractory disease are eligible.

      In Part 1, dose escalations cohorts are followed until dose-limiting toxicity (DLT) or a
      maximum tolerated dose (MTD) or RecommendedPart2Dose (RP2D) is defined. Dose escalation
      decisions will be made by the Data Review Committee and will be primarily guided by safety
      data observed through the end of Cycle 1, as well as on-going assessment of safety beyond
      Cycle 1 in later cohorts.

      Part 2 will begin once the MTD or RP2D is determined in Part 1. Part 2 will further
      characterize the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD),
      immunogenicity and to assess preliminary efficacy of MCLA-117. This part will enroll
      approximately 30 evaluable patients (defined as evaluable for first efficacy assessment).

      For both parts, the study consists of 3 periods: a Screening period (up to 28 days prior to
      the first dose of study drug); a Treatment period (first dose of study drug until the last
      dose of study drug with treatment cycles of 28 days); and a Follow Up period (through 30 days
      after the last dose and quarterly checks for survival data for up to 1 year). Participants'
      safety will be monitored throughout the study. Patients will be permitted to receive MCLA-117
      beyond Cycle 1 if conditions allow this.

      Number of Sites:

      Approximately 15 centers in five countries are estimated to be involved during Parts 1 and 2
      of the study. Additional sites may be added to ensure there is an acceptable enrollment rate
      or to replace non-enrolling/withdrawn sites.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Number of participants with Dose Limiting Toxicities (DLT)
time frame: 28 days
description: Evaluation of number of participants with treatment related toxicity observed during a dose escalation step for 1 Cycle
measure: Maximum plasma concentration [Cmax]
time frame: Day 22 predose, 5 minutes prior to End of Infusion (EOI), 1h, 2h, 4h, 8h, 24h, 72h, 6 days after EOI
description: Maximum plasma concentration [Cmax] as measured from all individual plasma concentrations
measure: Clearance of plasma
time frame: Day 22 predose, 5 minutes prior to End of Infusion (EOI), 1h, 2h, 4h, 8h, 24h, 72h, 6 days after EOI
description: Clearance of plasma
measure: Volume of distribution at steady state [Vss]
time frame: Day 22 predose, 5 minutes prior to End of Infusion (EOI), 1h, 2h, 4h, 8h, 24h, 72h, 6 days after EOI
description: Volume of distribution at steady state [Vss]
measure: Time to reach maximum plasma concentration [Tmax]
time frame: Day 22 predose, 5 minutes prior to End of Infusion (EOI), 1h, 2h, 4h, 8h, 24h, 72h, 6 days after EOI
description: Time to reach maximum plasma concentration [Tmax]
measure: Half-life [t1/2]
time frame: Day 22 predose, 5 minutes prior to End of Infusion (EOI), 1h, 2h, 4h, 8h, 24h, 72h, 6 days after EOI
description: Half-life [t1/2] calculated as time from all individual plasma concentrations to reach 50% of maximum concentration
measure: Area under the concentration versus time curve from time zero to time t [AUC0-t]
time frame: 1 week
description: Area under the concentration versus time curve [AUC0-t]
measure: Incidence of AntiDrugAntibodies (ADA) against MCLA-117
time frame: 24 months
description: Number of participants with ADAs against MCLA-117 as measured in serum
measure: Serum titer of ADAs against MCLA-117
time frame: Day 1 of each cycle
description: Serum titer of ADAs against MCLA-117 as measured in serum
measure: Serum titer of ADAs against MCLA-117
time frame: Day 28 of each cycle
description: Serum titer of ADAs against MCLA-117 as measured in serum
measure: Cytokine levels
time frame: Cycle 1: Day 1, 4, 8 and 28 at predose, 4h and 24h after end of infusion
description: Change in profile of cytokine upon administration of MCLA-117 compared to baseline
measure: Number of myeloblasts
time frame: Day 1 of every cycle and through study completion, an average of 2 months
description: number of blasts in peripheral blood and in bone marrow
measure: Objective response
time frame: Day 1 of every cycle and through study completion, an average of 2 months
description: Objective response is assessed by Cheson 2003
arm group label: MCLA-117 bispecific antibody
arm group type: Experimental
description: Dose escalation cohorts, with escalating doses of MCLA-117 until MTD or RP2D is reached. The dose is given weekly after initial ramp-up dosing steps. Each Cycle is 28 days. Single agent treatment.
Part 2-Expansion Cohort: The RP2D of MCLA-117 is given weekly after initial ramp-up dosing steps. Each Cycle is 28 days. Single agent treatment.
intervention type: Drug
intervention name: MCLA-117 bispecific antibody
description: MCLA-117, a human bispecific IgG antibody which targets CLEC12A and CD3
arm group label: MCLA-117 bispecific antibody
other name: bispecific
other name: human bispecific common light chain
other name: bispecific IgG1 targeting CLEC12A and CD3
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Jorge Cortes, MD, PhD
role: Principal Investigator
affiliation: Independent Protocol Advisor
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Belgium
country: France
country: Italy
country: Netherlands
country: United States
responsible party type: Sponsor
mesh term: Leukemia
mesh term: Leukemia, Myeloid
mesh term: Leukemia, Myeloid, Acute
mesh term: Antibodies
mesh term: Antibodies, Bispecific
sharing ipd: No